Akcie v oběhu společnosti Inhibrx
Jaká je hodnota metriky Akcie v oběhu společnosti Inhibrx?
Hodnota metriky Akcie v oběhu společnosti Inhibrx, Inc. je 18.847M 43.28%
Jaká je definice metriky Akcie v oběhu?
Akce v oběhu (Shares float) je podíl akcií společnosti vlastněných veřejnými investory vůči zablokovaným akcím (nejsou volně v oběhu).
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Akcie v oběhu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Inhibrx
Čemu se věnuje společnost Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou akcie v oběhu podobnou společnosti Inhibrx
- Hodnota metriky Akcie v oběhu společnosti Nesco je 18.823M 26.71%
- Hodnota metriky Akcie v oběhu společnosti Equillium je 18.825M
- Hodnota metriky Akcie v oběhu společnosti Stolt-Nielsen je 18.830M 35.18%
- Hodnota metriky Akcie v oběhu společnosti Stolt-Nielsen je 18.830M 30.91%
- Hodnota metriky Akcie v oběhu společnosti Lument Finance Trust je 18.832M 75.50%
- Hodnota metriky Akcie v oběhu společnosti BlueCity je 18.839M 51.07%
- Hodnota metriky Akcie v oběhu společnosti Inhibrx je 18.847M 43.28%
- Hodnota metriky Akcie v oběhu společnosti Sri Adhikari Brothers Television Network je 18.849M 53.94%
- Hodnota metriky Akcie v oběhu společnosti Trinity Exploration & Production Plc je 18.864M 48.52%
- Hodnota metriky Akcie v oběhu společnosti Stoke Therapeutics je 18.870M 47.86%
- Hodnota metriky Akcie v oběhu společnosti Oracle Services Software je 18.874M 21.95%
- Hodnota metriky Akcie v oběhu společnosti Bactiguard AB (publ) je 18.907M 56.77%
- Hodnota metriky Akcie v oběhu společnosti Safe Harbour plc je 18.917M 69.42%